Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Sodium-glucose cotransporter-2 inhibitors and other off-label therapies
7 evidence topics · 4 sources
EASL-EASD-EASO recommendation on SGLT2 inhibitors and metformin as MASH-targeted therapy
EASL-EASD-EASO statement on statins, fibrates, ezetimibe, and silymarin as MASH treatment
ADA Standards of Care 2026: glucose-lowering therapies other than pioglitazone and GLP-1 RAs in adults with type 2 diabetes and MASLD
“In adults with type 2 diabetes and MASLD, use of glucose-lowering therapies other than pioglitazone or GLP-1 RAs may be continued as clinically indicated, but these therapies lack evidence of benefit in MASH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“reduce hepatic steatosis, but their effects on steatohepatitis remain unknown.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, these agents have either failed to improve steatohepatitis in paired-biopsy studies (metformin) or have no RCTs with liver histological end points (i.e., sulfonylureas, glitinides, dipeptidyl peptidase 4 inhibitors, or acarbose).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
AASLD 2023 practice guidance on SGLT2 inhibitors, metformin, ursodeoxycholic acid, DPP-4 inhibitors, statins, and silymarin
“Available studies evaluating the role of SGLT-2i in the treatment of NAFLD/NASH are limited by relatively small sample sizes and lack of histological outcomes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Within these limitations, available data suggest SGLT-2i improve hepatic steatosis; however, the therapeutic impact of SGLT-2i on liver histology needs to be better defined.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Metformin, ursodeoxycholic acid, dipeptidylpeptidase-4, statins, and silymarin are well studied in NASH and should not be used as a treatment for NASH as they do not offer a meaningful histological benefit.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dapagliflozin phase 3 trial (DEAN): design, population, and setting
“Multicentre, double blind, randomised, placebo controlled trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Six tertiary hospitals in China from 23 November 2018 to 28 March 2023.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“154 adults with biopsy diagnosed MASH, with or without type 2 diabetes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All participants were randomly assigned to receive 10 mg orally of dapagliflozin or matching placebo once daily for 48 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 33% participants (51/154) had stage F1 fibrosis, 45% (70/154) had stage F2, and 19% (29/154) had stage F3.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dapagliflozin phase 3 trial (DEAN): histologic results at 48 weeks, intention-to-treat analysis
“Analyses used the intention-to-treat dataset.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MASH improvement without worsening of fibrosis was reported in 53% (41/78) of participants in the dapagliflozin group and 30% (23/76) in the placebo group (risk ratio 1.73 (95% confidence interval (CI) 1.16 to 2.58); P=0.006).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MASH resolution without worsening of fibrosis occurred in 23% (18/78) of participants in the dapagliflozin group and 8% (6/76) in the placebo group (risk ratio 2.91 (95% CI 1.22 to 6.97); P=0.01). Fibrosis improvement without worsening of MASH was reported in 45% (35/78) of participants in the dapagliflozin group, as compared with 20% (15/76) in the placebo group (risk ratio 2.25 (95% CI 1.35 to 3.75); P=0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dapagliflozin phase 3 trial (DEAN): limitations stated by the authors
“Firstly, our primary endpoint was MASH improvement without worsening of liver fibrosis instead of MASH resolution without worsening of fibrosis or fibrosis improvement without worsening of MASH according to the guidance of FDA” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Secondly, the current trial was conducted in a Chinese population, which limits the broader generalisability of the conclusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Finally, because of the scarcity of major adverse liver outcomes (eg, cirrhosis and hepatocellular carcinoma), large scale and long term trials are needed to further confirm these effects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote